Indexado em
  • Abra o Portão J
  • Genamics JournalSeek
  • CiteFactor
  • cosmos SE
  • Scimago
  • Diretório de Periódicos de Ulrich
  • Biblioteca de periódicos eletrônicos
  • RefSeek
  • Universidade de Hamdard
  • EBSCO AZ
  • Diretório de Indexação de Resumos para Periódicos
  • OCLC- WorldCat
  • Invocação Proquest
  • Scholarsteer
  • ESTRADA
  • Biblioteca Virtual de Biologia (vifabio)
  • publons
  • Fundação de Genebra para Educação e Pesquisa Médica
  • Google Scholar
Compartilhe esta página
Folheto de jornal
Flyer image

Abstrato

Serological Criteria for Mild, Moderate and Severe Atrophy in Atrophic Gastritis

Sergey Mikhailovich Kotelevets and Sergey Anatolievich Chekh

The study was carried out in a group of 360 dyspeptic Helicobacter pylori-infected patients. These patients were tested for markers of atrophy of the mucous membrane of the antrum section (gastrin-17) and corpus of stomach (pepsinogen-1). The markers were detected via the test panel for immune-enzyme analysis - "GastroPanel". All the 360 patients underwent the upper gastrointestinal endoscopy with subsequent biopsy of the antral and corpus mucosa. These markers were identified for a group of patients with severe atrophic gastritis and for a group of patients with mild and moderate atrophy. The level of the gastrin-17 was determined for the number of patients with mild, moderate and severe antral atrophic gastritis, which was identified with the use of upper gastrointestinal endoscopy followed by a biopsy of the antral mucosa. The level of the gastrin-17 in the serum was: mild antral atrophy - 7 ≤ pmol/L 0 10, moderate antral atrophy – 4 ≤ pmol/L <7, severe antral atrophy - 0 ≤ pmol/L < 4, no atrophy - 10 ≤ pmol/L. The level of the pepsinogen-1 was determined for the number of patients with mild, moderate and severe corpus atrophic gastritis, which was identified with the use of upper gastrointestinal endoscopy followed by a biopsy of the corpus mucosa. The bounds of the pepsinogen-1 level in the serum were: mild corpus atrophy - 15 ≤ µg/L <25, moderate corpus atrophy – 9 ≤ µg/L <15, severe corpus atrophy - 0 ≤ µg/L <9, no corpus atrophy - 25 ≤ µg/L. Rising of the effectiveness of serological screening considering the lines of serological markers severe atrophy and detected patients with high risk gastric cancer allows to avoid the upper gastrointestinal endoscopy